TW202045505A - 用於疾病之治療之新穎化合物及其醫藥組合物 - Google Patents
用於疾病之治療之新穎化合物及其醫藥組合物 Download PDFInfo
- Publication number
- TW202045505A TW202045505A TW109105861A TW109105861A TW202045505A TW 202045505 A TW202045505 A TW 202045505A TW 109105861 A TW109105861 A TW 109105861A TW 109105861 A TW109105861 A TW 109105861A TW 202045505 A TW202045505 A TW 202045505A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- pyridin
- pyrazolo
- carboxylic acid
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 382
- 238000011282 treatment Methods 0.000 title claims abstract description 70
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 38
- 201000010099 disease Diseases 0.000 title description 29
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 28
- 230000002124 endocrine Effects 0.000 claims abstract description 18
- 235000016709 nutrition Nutrition 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims description 151
- 125000000217 alkyl group Chemical group 0.000 claims description 114
- 125000005842 heteroatom Chemical group 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 38
- 125000005843 halogen group Chemical group 0.000 claims description 37
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 229910052717 sulfur Inorganic materials 0.000 claims description 25
- 208000030159 metabolic disease Diseases 0.000 claims description 24
- 208000030172 endocrine system disease Diseases 0.000 claims description 23
- 125000004429 atom Chemical group 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 125000002950 monocyclic group Chemical group 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 17
- 125000002541 furyl group Chemical group 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000000335 thiazolyl group Chemical group 0.000 claims description 10
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 9
- 125000002971 oxazolyl group Chemical group 0.000 claims description 9
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 230000004060 metabolic process Effects 0.000 claims description 7
- 230000035764 nutrition Effects 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 208000030212 nutrition disease Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 75
- 230000002503 metabolic effect Effects 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 239000011541 reaction mixture Substances 0.000 description 115
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 99
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 97
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 93
- 239000000203 mixture Substances 0.000 description 89
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 84
- 239000000243 solution Substances 0.000 description 66
- -1 n-propenyl Chemical group 0.000 description 62
- 235000019439 ethyl acetate Nutrition 0.000 description 49
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 44
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 40
- 208000008589 Obesity Diseases 0.000 description 39
- 235000020824 obesity Nutrition 0.000 description 38
- 206010012601 diabetes mellitus Diseases 0.000 description 35
- 239000007787 solid Substances 0.000 description 35
- 208000031226 Hyperlipidaemia Diseases 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- 239000002253 acid Substances 0.000 description 32
- 238000003786 synthesis reaction Methods 0.000 description 32
- 239000000460 chlorine Substances 0.000 description 31
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 238000003818 flash chromatography Methods 0.000 description 30
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 28
- 239000008103 glucose Substances 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 27
- 229910052731 fluorine Inorganic materials 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 229910052801 chlorine Inorganic materials 0.000 description 23
- 102000004877 Insulin Human genes 0.000 description 22
- 108090001061 Insulin Proteins 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 229940125396 insulin Drugs 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- IHCCAYCGZOLTEU-UHFFFAOYSA-N 3-furoic acid Chemical compound OC(=O)C=1C=COC=1 IHCCAYCGZOLTEU-UHFFFAOYSA-N 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 19
- 229940124597 therapeutic agent Drugs 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 239000012141 concentrate Substances 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 18
- WQOAKXFBWOXJNG-UHFFFAOYSA-N 5-bromopyrazolo[1,5-a]pyridine Chemical compound C1=C(Br)C=CN2N=CC=C21 WQOAKXFBWOXJNG-UHFFFAOYSA-N 0.000 description 17
- 108091000080 Phosphotransferase Proteins 0.000 description 17
- 102000020233 phosphotransferase Human genes 0.000 description 17
- 239000003981 vehicle Substances 0.000 description 17
- 206010022489 Insulin Resistance Diseases 0.000 description 16
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 16
- 125000003118 aryl group Chemical group 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 229920000609 methyl cellulose Polymers 0.000 description 16
- 239000001923 methylcellulose Substances 0.000 description 16
- 235000010981 methylcellulose Nutrition 0.000 description 16
- 208000019180 nutritional disease Diseases 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 201000001421 hyperglycemia Diseases 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 15
- LOFDXZJSDVCYAS-UHFFFAOYSA-N Ethyl 3-furoate Chemical compound CCOC(=O)C=1C=COC=1 LOFDXZJSDVCYAS-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000013058 crude material Substances 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 208000001145 Metabolic Syndrome Diseases 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 13
- 230000037213 diet Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000007429 general method Methods 0.000 description 12
- 210000002216 heart Anatomy 0.000 description 12
- ILULYDJFTJKQAP-UHFFFAOYSA-N hydron;propan-2-ylhydrazine;chloride Chemical compound [Cl-].CC(C)N[NH3+] ILULYDJFTJKQAP-UHFFFAOYSA-N 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 208000032928 Dyslipidaemia Diseases 0.000 description 11
- 206010020772 Hypertension Diseases 0.000 description 11
- 208000017170 Lipid metabolism disease Diseases 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 11
- 208000006575 hypertriglyceridemia Diseases 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 230000000155 isotopic effect Effects 0.000 description 11
- 229960003105 metformin Drugs 0.000 description 11
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- OPMFFAOEPFATTG-UHFFFAOYSA-N 2,2,2-trifluoroethylhydrazine Chemical compound NNCC(F)(F)F OPMFFAOEPFATTG-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 201000001320 Atherosclerosis Diseases 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 10
- 208000002705 Glucose Intolerance Diseases 0.000 description 10
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 10
- 206010019280 Heart failures Diseases 0.000 description 10
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 10
- 208000002720 Malnutrition Diseases 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 206010047139 Vasoconstriction Diseases 0.000 description 10
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 10
- 201000008980 hyperinsulinism Diseases 0.000 description 10
- 230000001071 malnutrition Effects 0.000 description 10
- 235000000824 malnutrition Nutrition 0.000 description 10
- 208000015380 nutritional deficiency disease Diseases 0.000 description 10
- 201000009104 prediabetes syndrome Diseases 0.000 description 10
- 230000025033 vasoconstriction Effects 0.000 description 10
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 10
- 230000002159 abnormal effect Effects 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 230000002285 radioactive effect Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 8
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000017701 Endocrine disease Diseases 0.000 description 7
- 208000004930 Fatty Liver Diseases 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- 108010013866 PAS domain kinases Proteins 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 208000016097 disease of metabolism Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 7
- 235000009200 high fat diet Nutrition 0.000 description 7
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000003566 oxetanyl group Chemical group 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 6
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 6
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 6
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 6
- 238000006069 Suzuki reaction reaction Methods 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- CIPMPQGRFNDLAP-UHFFFAOYSA-N ethyl 1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=CS1 CIPMPQGRFNDLAP-UHFFFAOYSA-N 0.000 description 6
- DUMHBFMURBWDPC-UHFFFAOYSA-N ethylhydrazine;oxalic acid Chemical compound CCNN.OC(=O)C(O)=O DUMHBFMURBWDPC-UHFFFAOYSA-N 0.000 description 6
- 208000010706 fatty liver disease Diseases 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 125000002883 imidazolyl group Chemical group 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 125000003367 polycyclic group Chemical group 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 125000000168 pyrrolyl group Chemical group 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- 206010000599 Acromegaly Diseases 0.000 description 5
- 206010002329 Aneurysm Diseases 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 200000000007 Arterial disease Diseases 0.000 description 5
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 5
- 208000014311 Cushing syndrome Diseases 0.000 description 5
- 229930091371 Fructose Natural products 0.000 description 5
- 239000005715 Fructose Substances 0.000 description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- 208000004196 Heart Aneurysm Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 5
- 208000019695 Migraine disease Diseases 0.000 description 5
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 5
- 206010033649 Pancreatitis chronic Diseases 0.000 description 5
- 208000018262 Peripheral vascular disease Diseases 0.000 description 5
- 208000001280 Prediabetic State Diseases 0.000 description 5
- 206010063837 Reperfusion injury Diseases 0.000 description 5
- 206010044541 Traumatic shock Diseases 0.000 description 5
- 206010047115 Vasculitis Diseases 0.000 description 5
- 235000021068 Western diet Nutrition 0.000 description 5
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 5
- 230000006793 arrhythmia Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000002393 azetidinyl group Chemical group 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 125000000532 dioxanyl group Chemical group 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- JSIHGJOTCFFUFC-UHFFFAOYSA-N ethyl 4-methoxy-2-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound COC=1N=C(SC=1C(=O)OCC)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C)C JSIHGJOTCFFUFC-UHFFFAOYSA-N 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 208000018578 heart valve disease Diseases 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 5
- 230000001969 hypertrophic effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 125000001786 isothiazolyl group Chemical group 0.000 description 5
- 125000000842 isoxazolyl group Chemical group 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 208000011661 metabolic syndrome X Diseases 0.000 description 5
- 206010027599 migraine Diseases 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000000414 obstructive effect Effects 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 125000004193 piperazinyl group Chemical group 0.000 description 5
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- MRTAVLDNYYEJHK-UHFFFAOYSA-M sodium;2-chloro-2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)(F)Cl MRTAVLDNYYEJHK-UHFFFAOYSA-M 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 5
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 5
- 125000001425 triazolyl group Chemical group 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 208000019553 vascular disease Diseases 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 5
- JRHPOFJADXHYBR-HTQZYQBOSA-N (1r,2r)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@@H]1CCCC[C@H]1NC JRHPOFJADXHYBR-HTQZYQBOSA-N 0.000 description 4
- MNKCGUKVRJZKEQ-MIXQCLKLSA-N (1z,5z)-cycloocta-1,5-diene;iridium;methanol Chemical compound [Ir].[Ir].OC.OC.C\1C\C=C/CC\C=C/1.C\1C\C=C/CC\C=C/1 MNKCGUKVRJZKEQ-MIXQCLKLSA-N 0.000 description 4
- KYIAWMUMQJDKCS-UHFFFAOYSA-N 3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazole Chemical compound CC=1C=C(C)N(CC(F)(F)F)N=1 KYIAWMUMQJDKCS-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- ITJXENTYAVEDPA-UHFFFAOYSA-N 5-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound C(C)(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C1=CC(=CO1)C(=O)O)C ITJXENTYAVEDPA-UHFFFAOYSA-N 0.000 description 4
- AIHOJUYAEVOTTP-UHFFFAOYSA-N 5-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound CC1=C(C(=NN1CC(F)(F)F)C)C2=C3C=C(C=CN3N=C2)C4=CC(=CO4)C(=O)O AIHOJUYAEVOTTP-UHFFFAOYSA-N 0.000 description 4
- 206010007513 Cardiac aneurysm Diseases 0.000 description 4
- 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 4
- 108010089790 Eukaryotic Initiation Factor-3 Proteins 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 208000025368 adrenal gland disease Diseases 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 230000001746 atrial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- FNJVDWXUKLTFFL-UHFFFAOYSA-N diethyl 2-bromopropanedioate Chemical compound CCOC(=O)C(Br)C(=O)OCC FNJVDWXUKLTFFL-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- NTSMZTQSTHLDNQ-UHFFFAOYSA-N ethyl 4-ethoxy-2-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound C(C)OC=1N=C(SC=1C(=O)OCC)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C)C NTSMZTQSTHLDNQ-UHFFFAOYSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000007410 oral glucose tolerance test Methods 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical class COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- IKSLHZIIYLOOFJ-UHFFFAOYSA-N (2-chloro-2,2-difluoroethyl) acetate Chemical compound CC(=O)OCC(F)(F)Cl IKSLHZIIYLOOFJ-UHFFFAOYSA-N 0.000 description 3
- SHXHPUAKLCCLDV-UHFFFAOYSA-N 1,1,1-trifluoropentane-2,4-dione Chemical compound CC(=O)CC(=O)C(F)(F)F SHXHPUAKLCCLDV-UHFFFAOYSA-N 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- JPLDHENOADEEAY-UHFFFAOYSA-N 1-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylic acid Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)N1N=CC(=C1)C(=O)O)C JPLDHENOADEEAY-UHFFFAOYSA-N 0.000 description 3
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 3
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- SDZVRBRVKPSFEV-UHFFFAOYSA-N 3-bromopyrazolo[1,5-a]pyridine-5-carbonitrile Chemical compound C1=CC(C#N)=CC2=C(Br)C=NN21 SDZVRBRVKPSFEV-UHFFFAOYSA-N 0.000 description 3
- CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical compound OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 description 3
- IFCNTZRBBLIUMD-UHFFFAOYSA-N 4-bromo-1,5-dimethyl-3-(trifluoromethyl)pyrazole Chemical compound CC1=C(Br)C(C(F)(F)F)=NN1C IFCNTZRBBLIUMD-UHFFFAOYSA-N 0.000 description 3
- RISOHYOEPYWKOB-UHFFFAOYSA-N 4-bromo-3,5-dimethyl-1h-pyrazole Chemical compound CC1=NNC(C)=C1Br RISOHYOEPYWKOB-UHFFFAOYSA-N 0.000 description 3
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 description 3
- XYBPFWUNJQTZCM-UHFFFAOYSA-N 5-bromofuran-3-carboxylic acid Chemical compound OC(=O)C1=COC(Br)=C1 XYBPFWUNJQTZCM-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 3
- 102000003729 Neprilysin Human genes 0.000 description 3
- 108090000028 Neprilysin Proteins 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000035578 autophosphorylation Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 3
- CNQYPGDMCBJWCI-UHFFFAOYSA-N ethyl 2-bromo-4-(trifluoromethyl)-1,3-oxazole-5-carboxylate Chemical compound CCOC(=O)C=1OC(Br)=NC=1C(F)(F)F CNQYPGDMCBJWCI-UHFFFAOYSA-N 0.000 description 3
- SYWQOPRAPDMWMC-UHFFFAOYSA-N ethyl 2-chloro-1,3-oxazole-4-carboxylate Chemical compound CCOC(=O)C1=COC(Cl)=N1 SYWQOPRAPDMWMC-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 235000019137 high fructose diet Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- ZFBQRIPCGDCQDF-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine-5-carbonitrile Chemical compound C1=C(C#N)C=CN2N=CC=C21 ZFBQRIPCGDCQDF-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000003797 solvolysis reaction Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 229910052727 yttrium Inorganic materials 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 2
- YZVFSQQHQPPKNX-UHFFFAOYSA-N 1,3-thiazole-5-carboxylic acid Chemical compound OC(=O)C1=CN=CS1 YZVFSQQHQPPKNX-UHFFFAOYSA-N 0.000 description 2
- MWLSGOBZEJEEPI-UHFFFAOYSA-N 1-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylic acid Chemical compound CN1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)N1N=CC(=C1)C(=O)O)C MWLSGOBZEJEEPI-UHFFFAOYSA-N 0.000 description 2
- ZQHUBJQXYQGGGB-UHFFFAOYSA-N 1-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-3-methoxypyrazole-4-carboxylic acid Chemical compound C(C)(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)N1N=C(C(=C1)C(=O)O)OC)C ZQHUBJQXYQGGGB-UHFFFAOYSA-N 0.000 description 2
- WCPRSSNELCJSMC-UHFFFAOYSA-N 1-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylic acid Chemical compound C(C)(C)N1N=C(C(=C1C)C=1C=NN2C1C=C(C=C2)N2N=CC(=C2)C(=O)O)C WCPRSSNELCJSMC-UHFFFAOYSA-N 0.000 description 2
- KSMFBNXXUXYJNA-UHFFFAOYSA-N 1-[3-[1-(difluoromethyl)-3,5-dimethylpyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-3-methoxypyrazole-4-carboxylic acid Chemical compound FC(N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)N1N=C(C(=C1)C(=O)O)OC)C)F KSMFBNXXUXYJNA-UHFFFAOYSA-N 0.000 description 2
- WARVWAZVSHGRDQ-UHFFFAOYSA-N 1-[3-[1-(difluoromethyl)-3,5-dimethylpyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylic acid Chemical compound FC(N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)N1N=CC(=C1)C(=O)O)C)F WARVWAZVSHGRDQ-UHFFFAOYSA-N 0.000 description 2
- YWXZLXJWDFNOIW-UHFFFAOYSA-N 1-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-3-(trifluoromethyl)pyrazole-4-carboxylic acid Chemical compound CC1=C(C(=NN1CC(F)(F)F)C)C2=C3C=C(C=CN3N=C2)N4C=C(C(=N4)C(F)(F)F)C(=O)O YWXZLXJWDFNOIW-UHFFFAOYSA-N 0.000 description 2
- HQXSHHDUWGSLJE-UHFFFAOYSA-N 1-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-3-methoxypyrazole-4-carboxylic acid Chemical compound CC1=NN(C(=C1C=1C=NN2C1C=C(C=C2)N2N=C(C(=C2)C(=O)O)OC)C)CC(F)(F)F HQXSHHDUWGSLJE-UHFFFAOYSA-N 0.000 description 2
- JDYMYYSJFLFRQE-UHFFFAOYSA-N 1-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylic acid Chemical compound CC1=C(C(=NN1CC(F)(F)F)C)C2=C3C=C(C=CN3N=C2)N4C=C(C=N4)C(=O)O JDYMYYSJFLFRQE-UHFFFAOYSA-N 0.000 description 2
- NFLAQPONOVPKIX-UHFFFAOYSA-N 1-[3-[5-methyl-1-propan-2-yl-3-(trifluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylic acid Chemical compound C(C)(C)N1N=C(C(=C1C)C=1C=NN2C1C=C(C=C2)N2N=CC(=C2)C(=O)O)C(F)(F)F NFLAQPONOVPKIX-UHFFFAOYSA-N 0.000 description 2
- PHIQRCUIOIVTMC-UHFFFAOYSA-N 2,2-dimethylpropanoyloxymethyl 5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound N12C=CC(=CC1=C(C=N2)C1=C(C)N(N=C1C)C)C1=CC(C(=O)OCOC(=O)C(C)(C)C)=CO1 PHIQRCUIOIVTMC-UHFFFAOYSA-N 0.000 description 2
- IEKJZDRXPYBFDI-UHFFFAOYSA-N 2-(2-methylpropyl)-5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound C(C(C)C)C=1OC(=CC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C)C IEKJZDRXPYBFDI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WQFAFGANGDIUJO-UHFFFAOYSA-N 2-[3-(1,5-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-oxazole-4-carboxylic acid Chemical compound CC1=C(C=NN1C)C2=C3C=C(C=CN3N=C2)C4=NC(=CO4)C(=O)O WQFAFGANGDIUJO-UHFFFAOYSA-N 0.000 description 2
- OWATXFDUKBNRQQ-UHFFFAOYSA-N 2-[3-(1-ethyl-3,5-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound C(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C=1SC(=CN=1)C(=O)O)C OWATXFDUKBNRQQ-UHFFFAOYSA-N 0.000 description 2
- OXVJJHDYUALPEM-UHFFFAOYSA-N 2-[3-(1-ethyl-3,5-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylic acid Chemical compound C(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C=1SC(=C(N=1)OC)C(=O)O)C OXVJJHDYUALPEM-UHFFFAOYSA-N 0.000 description 2
- GBDCJQRPFMGOBW-UHFFFAOYSA-N 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-oxazole-4-carboxylic acid Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1OC=C(N=1)C(=O)O)C GBDCJQRPFMGOBW-UHFFFAOYSA-N 0.000 description 2
- MFCYPRHELLJGTI-UHFFFAOYSA-N 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-oxazole-5-carboxylic acid Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1OC(=CN=1)C(=O)O)C MFCYPRHELLJGTI-UHFFFAOYSA-N 0.000 description 2
- ZOUWUPXTFYRAPC-UHFFFAOYSA-N 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1SC(=CN=1)C(=O)O)C ZOUWUPXTFYRAPC-UHFFFAOYSA-N 0.000 description 2
- YGBFTCDLQZZMOS-UHFFFAOYSA-N 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-(2-ethoxyethoxy)-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1SC(=C(N=1)OCCOCC)C(=O)O)C YGBFTCDLQZZMOS-UHFFFAOYSA-N 0.000 description 2
- IOCOBVIFIDHUDA-UHFFFAOYSA-N 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-(2-methoxyethoxy)-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1SC(=C(N=1)OCCOC)C(=O)O)C IOCOBVIFIDHUDA-UHFFFAOYSA-N 0.000 description 2
- HCJDLOXAJYANJE-UHFFFAOYSA-N 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-(trifluoromethyl)-1,3-oxazole-5-carboxylic acid Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1OC(=C(N=1)C(F)(F)F)C(=O)O)C HCJDLOXAJYANJE-UHFFFAOYSA-N 0.000 description 2
- ORBQLTJFNWNUNK-UHFFFAOYSA-N 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-ethoxy-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1SC(=C(N=1)OCC)C(=O)O)C ORBQLTJFNWNUNK-UHFFFAOYSA-N 0.000 description 2
- YTLUKRNNGNZIRY-UHFFFAOYSA-N 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-5-methyl-1,3-oxazole-4-carboxylic acid Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1OC(=C(N=1)C(=O)O)C)C YTLUKRNNGNZIRY-UHFFFAOYSA-N 0.000 description 2
- YOWQHCFVRZNQIG-UHFFFAOYSA-N 2-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound C(C)(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C=1SC(=CN=1)C(=O)O)C YOWQHCFVRZNQIG-UHFFFAOYSA-N 0.000 description 2
- MSCRHZCARFLCRG-UHFFFAOYSA-N 2-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-ethoxy-1,3-thiazole-5-carboxylic acid Chemical compound C(C)OC=1N=C(SC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C(C)C)C MSCRHZCARFLCRG-UHFFFAOYSA-N 0.000 description 2
- IHOQTWTZOZVJNZ-UHFFFAOYSA-N 2-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylic acid Chemical compound C(C)(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C=1SC(=C(N=1)OC)C(=O)O)C IHOQTWTZOZVJNZ-UHFFFAOYSA-N 0.000 description 2
- APANGCGYDCOTDV-UHFFFAOYSA-N 2-[3-[1,5-dimethyl-3-(trifluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-1,3-oxazole-4-carboxylic acid Chemical compound CN1N=C(C(=C1C)C=1C=NN2C1C=C(C=C2)C=2OC=C(N2)C(=O)O)C(F)(F)F APANGCGYDCOTDV-UHFFFAOYSA-N 0.000 description 2
- CICZQIYHZLMSGW-UHFFFAOYSA-N 2-[3-[1-(difluoromethyl)-3,5-dimethylpyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-1,3-oxazole-5-carboxylic acid Chemical compound FC(N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C=1OC(=CN=1)C(=O)O)C)F CICZQIYHZLMSGW-UHFFFAOYSA-N 0.000 description 2
- GXKSZKCZFHNQGK-UHFFFAOYSA-N 2-[3-[1-(difluoromethyl)-3,5-dimethylpyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound FC(N1N=C(C(=C1C)C=1C=NN2C1C=C(C=C2)C=2SC(=CN2)C(=O)O)C)F GXKSZKCZFHNQGK-UHFFFAOYSA-N 0.000 description 2
- XIQFOAHGJLPRRM-UHFFFAOYSA-N 2-[3-[1-(difluoromethyl)-3,5-dimethylpyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-4-ethoxy-1,3-thiazole-5-carboxylic acid Chemical compound FC(N1N=C(C(=C1C)C=1C=NN2C1C=C(C=C2)C=2SC(=C(N2)OCC)C(=O)O)C)F XIQFOAHGJLPRRM-UHFFFAOYSA-N 0.000 description 2
- OWXZTQMCTCLWCH-UHFFFAOYSA-N 2-[3-[1-(difluoromethyl)-3,5-dimethylpyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylic acid Chemical compound FC(N1N=C(C(=C1C)C=1C=NN2C1C=C(C=C2)C=2SC(=C(N2)OC)C(=O)O)C)F OWXZTQMCTCLWCH-UHFFFAOYSA-N 0.000 description 2
- OBZZPQXLYBNIAD-UHFFFAOYSA-N 2-[3-[3,5-dimethyl-1-(1,1,1-trifluoropropan-2-yl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NN(C(=C1C=1C=NN2C1C=C(C=C2)C=2SC(=C(N2)OC)C(=O)O)C)C(C(F)(F)F)C OBZZPQXLYBNIAD-UHFFFAOYSA-N 0.000 description 2
- QKWASYHFXJCFPO-UHFFFAOYSA-N 2-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-4-ethoxy-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NN(C(=C1C=1C=NN2C1C=C(C=C2)C=2SC(=C(N2)OCC)C(=O)O)C)CC(F)(F)F QKWASYHFXJCFPO-UHFFFAOYSA-N 0.000 description 2
- DVMHAGAISODFIP-UHFFFAOYSA-N 2-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylic acid Chemical compound CC1=C(C(=NN1CC(F)(F)F)C)C2=C3C=C(C=CN3N=C2)C4=NC(=C(S4)C(=O)O)OC DVMHAGAISODFIP-UHFFFAOYSA-N 0.000 description 2
- OYMCMWPHMPODNK-UHFFFAOYSA-N 2-bromofuran Chemical compound BrC1=CC=CO1 OYMCMWPHMPODNK-UHFFFAOYSA-N 0.000 description 2
- SHPQMJRKYIRYRR-UHFFFAOYSA-N 2-cyclopropyl-5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound C1(CC1)C=1OC(=CC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C)C SHPQMJRKYIRYRR-UHFFFAOYSA-N 0.000 description 2
- YRSJVQUQJHCWAQ-UHFFFAOYSA-N 2-cyclopropyl-5-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound C1(CC1)C=1OC(=CC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NOC=1C)C YRSJVQUQJHCWAQ-UHFFFAOYSA-N 0.000 description 2
- XYEGGXXCKVWBHS-UHFFFAOYSA-N 2-ethyl-5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound C(C)C=1OC(=CC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C)C XYEGGXXCKVWBHS-UHFFFAOYSA-N 0.000 description 2
- AHANLIVUERSMRF-UHFFFAOYSA-N 2-methyl-5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound CC=1OC(=CC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C)C AHANLIVUERSMRF-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- FNLKHJYMDGUFHE-UHFFFAOYSA-N 4-(2,2,2-trifluoroethoxy)-2-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound FC(COC=1N=C(SC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C)C)(F)F FNLKHJYMDGUFHE-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QABYGIXTFRLYDE-UHFFFAOYSA-N 4-(difluoromethoxy)-2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound C1=CC(=CC=2N1N=CC=2C1=C(C)ON=C1C)C=1SC(C(=O)O)=C(N=1)OC(F)F QABYGIXTFRLYDE-UHFFFAOYSA-N 0.000 description 2
- MFCAMLAPZBYRTJ-UHFFFAOYSA-N 4-(difluoromethyl)-2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound FC(C=1N=C(SC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NOC=1C)C)F MFCAMLAPZBYRTJ-UHFFFAOYSA-N 0.000 description 2
- XEKNTJWGUXFRKE-UHFFFAOYSA-N 4-(difluoromethyl)-2-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound FC(C=1N=C(SC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C(C)C)C)F XEKNTJWGUXFRKE-UHFFFAOYSA-N 0.000 description 2
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical compound OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 description 2
- CXKZTTNVIBHWAQ-UHFFFAOYSA-N 4-bromo-3,5-dimethyl-1-propan-2-ylpyrazole Chemical compound CC(C)N1N=C(C)C(Br)=C1C CXKZTTNVIBHWAQ-UHFFFAOYSA-N 0.000 description 2
- DSUSVRZFAGGBIX-UHFFFAOYSA-N 4-cyclopropyl-2-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound C1(CC1)C=1N=C(SC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C)C DSUSVRZFAGGBIX-UHFFFAOYSA-N 0.000 description 2
- RPIHBSXXABHEAF-UHFFFAOYSA-N 4-cyclopropyl-2-[3-(1-ethyl-3,5-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound C1(CC1)C=1N=C(SC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)CC)C RPIHBSXXABHEAF-UHFFFAOYSA-N 0.000 description 2
- VFXXHZHWQXVHHR-UHFFFAOYSA-N 4-cyclopropyl-2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound C1(CC1)C=1N=C(SC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NOC=1C)C VFXXHZHWQXVHHR-UHFFFAOYSA-N 0.000 description 2
- RMUPABXRBNJYFC-UHFFFAOYSA-N 4-cyclopropyl-2-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound C1(CC1)C=1N=C(SC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C(C)C)C RMUPABXRBNJYFC-UHFFFAOYSA-N 0.000 description 2
- AFYHPYACXMMPOL-UHFFFAOYSA-N 4-cyclopropyl-2-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound C1(CC1)C=1N=C(SC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)CC(F)(F)F)C AFYHPYACXMMPOL-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- GVSVQCXMTUXNDT-UHFFFAOYSA-N 4-ethoxy-2-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound C(C)OC=1N=C(SC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C)C GVSVQCXMTUXNDT-UHFFFAOYSA-N 0.000 description 2
- VPZVDDSKCSFPRK-UHFFFAOYSA-N 4-ethoxy-2-[3-(1-ethyl-3,5-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound C(C)OC=1N=C(SC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)CC)C VPZVDDSKCSFPRK-UHFFFAOYSA-N 0.000 description 2
- MPRHCMOQQSNDFR-UHFFFAOYSA-N 4-methoxy-2-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylic acid Chemical compound COC=1N=C(SC=1C(=O)O)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C)C MPRHCMOQQSNDFR-UHFFFAOYSA-N 0.000 description 2
- OAZDGZOSXLXADH-UHFFFAOYSA-N 5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxamide Chemical compound C1=CC(=CC=2N1N=CC=2C1=C(C)N(N=C1C)C)C=1OC=C(C(=O)N)C=1 OAZDGZOSXLXADH-UHFFFAOYSA-N 0.000 description 2
- BFHZATNNNODGBA-UHFFFAOYSA-N 5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound CN1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C1=CC(=CO1)C(=O)O)C BFHZATNNNODGBA-UHFFFAOYSA-N 0.000 description 2
- LXTIIKMIXKIISC-UHFFFAOYSA-N 5-[3-(1,3-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound CN1N=C(C(=C1)C=1C=NN2C=1C=C(C=C2)C1=CC(=CO1)C(=O)O)C LXTIIKMIXKIISC-UHFFFAOYSA-N 0.000 description 2
- NFHFACFUUQEOTO-UHFFFAOYSA-N 5-[3-(1,5-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound CN1N=CC(=C1C)C=1C=NN2C=1C=C(C=C2)C1=CC(=CO1)C(=O)O NFHFACFUUQEOTO-UHFFFAOYSA-N 0.000 description 2
- XHPHNQXJVWRCKF-UHFFFAOYSA-N 5-[3-(1-ethyl-3,5-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound C(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C1=CC(=CO1)C(=O)O)C XHPHNQXJVWRCKF-UHFFFAOYSA-N 0.000 description 2
- FXKUQCJURQVOBA-UHFFFAOYSA-N 5-[3-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound CN1N=CC(=C1)C=1C=NN2C=1C=C(C=C2)C1=CC(=CO1)C(=O)O FXKUQCJURQVOBA-UHFFFAOYSA-N 0.000 description 2
- SEXTZPCJNCBTSU-UHFFFAOYSA-N 5-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-methylfuran-3-carboxylic acid Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C1=CC(=C(O1)C)C(=O)O)C SEXTZPCJNCBTSU-UHFFFAOYSA-N 0.000 description 2
- MENPVUOPVAIKSV-UHFFFAOYSA-N 5-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-2-carboxylic acid Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C1=CC=C(O1)C(=O)O)C MENPVUOPVAIKSV-UHFFFAOYSA-N 0.000 description 2
- LFZLFTBOAJQGOB-UHFFFAOYSA-N 5-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C1=CC(=CO1)C(=O)O)C LFZLFTBOAJQGOB-UHFFFAOYSA-N 0.000 description 2
- PQAWSVZJWMSMIS-UHFFFAOYSA-N 5-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-2-carboxylic acid Chemical compound C(C)(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C1=CC=C(O1)C(=O)O)C PQAWSVZJWMSMIS-UHFFFAOYSA-N 0.000 description 2
- LDBPHDYAMPJUKH-UHFFFAOYSA-N 5-[3-[1-(difluoromethyl)-3,5-dimethylpyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]furan-2-carboxylic acid Chemical compound FC(N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C1=CC=C(O1)C(=O)O)C)F LDBPHDYAMPJUKH-UHFFFAOYSA-N 0.000 description 2
- WXUITSNGZBECDS-UHFFFAOYSA-N 5-[3-[1-(difluoromethyl)-3,5-dimethylpyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound FC(N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C1=CC(=CO1)C(=O)O)C)F WXUITSNGZBECDS-UHFFFAOYSA-N 0.000 description 2
- DHEPKQNLLRQBHB-UHFFFAOYSA-N 5-[3-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylic acid Chemical compound CN1N=C(C(=C1)C=1C=NN2C=1C=C(C=C2)C1=CC(=CO1)C(=O)O)C(F)(F)F DHEPKQNLLRQBHB-UHFFFAOYSA-N 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 102100038495 Bile acid receptor Human genes 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- MQUBOZVLLPGAHG-UHFFFAOYSA-N CN1C(=C(C=C1)C=1C=NN2C=1C=C(C=C2)C=1OC=C(N=1)C(=O)OCC)C Chemical compound CN1C(=C(C=C1)C=1C=NN2C=1C=C(C=C2)C=1OC=C(N=1)C(=O)OCC)C MQUBOZVLLPGAHG-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 101000937129 Drosophila melanogaster Cadherin-related tumor suppressor Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 2
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- HDJLSECJEQSPKW-UHFFFAOYSA-N Methyl 2-Furancarboxylate Chemical compound COC(=O)C1=CC=CO1 HDJLSECJEQSPKW-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FLSNWIOTWQGEJE-UHFFFAOYSA-N N-cyclopropylsulfonyl-5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxamide Chemical compound C1=CC(=CC=2N1N=CC=2C1=C(C)N(N=C1C)C)C1=CC(C(=O)NS(=O)(=O)C2CC2)=CO1 FLSNWIOTWQGEJE-UHFFFAOYSA-N 0.000 description 2
- MEDHMDJYEODDRZ-UHFFFAOYSA-N N-methylsulfonyl-5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxamide Chemical compound CS(=O)(=O)NC(=O)C1=COC(=C1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)C)C MEDHMDJYEODDRZ-UHFFFAOYSA-N 0.000 description 2
- 101100221809 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cpd-7 gene Proteins 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000006887 Ullmann reaction Methods 0.000 description 2
- LEEDPQKQWFMDDP-UHFFFAOYSA-N [2-(dimethylamino)-2-oxoethyl] 5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound C1=C(C2=CC(C(=O)OCC(=O)N(C)C)=CO2)C=CN2C1=C(C=N2)C1=C(C)N(N=C1C)C LEEDPQKQWFMDDP-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
- 229960001058 bupropion Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- FWZHAFNJWNJYMQ-UHFFFAOYSA-N ethyl 1-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylate Chemical compound CN1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)N1N=CC(=C1)C(=O)OCC)C FWZHAFNJWNJYMQ-UHFFFAOYSA-N 0.000 description 2
- DWSCVYWBJPKWQH-UHFFFAOYSA-N ethyl 1-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylate Chemical compound C(C)(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)N1N=CC(=C1)C(=O)OCC)C DWSCVYWBJPKWQH-UHFFFAOYSA-N 0.000 description 2
- BWMMGZVQLFLDIY-UHFFFAOYSA-N ethyl 1-[3-[1-(difluoromethyl)-3,5-dimethylpyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-3-methoxypyrazole-4-carboxylate Chemical compound FC(N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)N1N=C(C(=C1)C(=O)OCC)OC)C)F BWMMGZVQLFLDIY-UHFFFAOYSA-N 0.000 description 2
- YZCDICHDKXKGNC-UHFFFAOYSA-N ethyl 1-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-3-(trifluoromethyl)pyrazole-4-carboxylate Chemical compound C(C)OC(=O)C=1C(=NN(C1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)CC(F)(F)F)C)C(F)(F)F YZCDICHDKXKGNC-UHFFFAOYSA-N 0.000 description 2
- HVGNRGLXYOTEJM-UHFFFAOYSA-N ethyl 1-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-3-methoxypyrazole-4-carboxylate Chemical compound C(C)OC(=O)C=1C(=NN(C1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)CC(F)(F)F)C)OC HVGNRGLXYOTEJM-UHFFFAOYSA-N 0.000 description 2
- LPCPBPGXKNXQTL-UHFFFAOYSA-N ethyl 1-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylate Chemical compound CCOC(=O)C1=CN(N=C1)C2=CC3=C(C=NN3C=C2)C4=C(N(N=C4C)CC(F)(F)F)C LPCPBPGXKNXQTL-UHFFFAOYSA-N 0.000 description 2
- KACZQOKEFKFNDB-UHFFFAOYSA-N ethyl 1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1 KACZQOKEFKFNDB-UHFFFAOYSA-N 0.000 description 2
- CNKKARMJPKUPDM-UHFFFAOYSA-N ethyl 2-[3-(1-ethyl-3,5-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylate Chemical compound C(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C=1SC(=C(N=1)OC)C(=O)OCC)C CNKKARMJPKUPDM-UHFFFAOYSA-N 0.000 description 2
- SCBNQOJQCMYHDQ-UHFFFAOYSA-N ethyl 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-oxazole-4-carboxylate Chemical compound CCOC(=O)C1=COC(=N1)C2=CC3=C(C=NN3C=C2)C4=C(ON=C4C)C SCBNQOJQCMYHDQ-UHFFFAOYSA-N 0.000 description 2
- TUUXGYAWEQFXSX-UHFFFAOYSA-N ethyl 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-oxazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(O1)C2=CC3=C(C=NN3C=C2)C4=C(ON=C4C)C TUUXGYAWEQFXSX-UHFFFAOYSA-N 0.000 description 2
- YKGOCULOFCCOBI-UHFFFAOYSA-N ethyl 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-(2-ethoxyethoxy)-1,3-thiazole-5-carboxylate Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1SC(=C(N=1)OCCOCC)C(=O)OCC)C YKGOCULOFCCOBI-UHFFFAOYSA-N 0.000 description 2
- BKPBYFHNQWMYCI-UHFFFAOYSA-N ethyl 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-(2-methoxyethoxy)-1,3-thiazole-5-carboxylate Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1SC(=C(N=1)OCCOC)C(=O)OCC)C BKPBYFHNQWMYCI-UHFFFAOYSA-N 0.000 description 2
- LWZHVAJXKRZADH-UHFFFAOYSA-N ethyl 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-ethoxy-1,3-thiazole-5-carboxylate Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1SC(=C(N=1)OCC)C(=O)OCC)C LWZHVAJXKRZADH-UHFFFAOYSA-N 0.000 description 2
- WRIZZIKZDVHTQT-UHFFFAOYSA-N ethyl 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylate Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1SC(=C(N=1)OC)C(=O)OCC)C WRIZZIKZDVHTQT-UHFFFAOYSA-N 0.000 description 2
- JMJNRCDOBGNMAD-UHFFFAOYSA-N ethyl 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-5-methyl-1,3-oxazole-4-carboxylate Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1OC(=C(N=1)C(=O)OCC)C)C JMJNRCDOBGNMAD-UHFFFAOYSA-N 0.000 description 2
- BRPSXKYNCBILLQ-UHFFFAOYSA-N ethyl 2-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-ethoxy-1,3-thiazole-5-carboxylate Chemical compound C(C)OC=1N=C(SC=1C(=O)OCC)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C(C)C)C BRPSXKYNCBILLQ-UHFFFAOYSA-N 0.000 description 2
- BHYABJXEGZHYMU-UHFFFAOYSA-N ethyl 2-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylate Chemical compound C(C)(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C=1SC(=C(N=1)OC)C(=O)OCC)C BHYABJXEGZHYMU-UHFFFAOYSA-N 0.000 description 2
- FLSCTDQHQLVRES-UHFFFAOYSA-N ethyl 2-[3-[1-(difluoromethyl)-3,5-dimethylpyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)C(F)F)C)OC FLSCTDQHQLVRES-UHFFFAOYSA-N 0.000 description 2
- ZAWQUHGOGHCZMC-UHFFFAOYSA-N ethyl 2-[3-[3,5-dimethyl-1-(1,1,1-trifluoropropan-2-yl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C1=C(N=C(S1)C2=CC3=C(C=NN3C=C2)C4=C(N(N=C4C)C(C)C(F)(F)F)C)OC ZAWQUHGOGHCZMC-UHFFFAOYSA-N 0.000 description 2
- XGKJBIXDFNAUCV-UHFFFAOYSA-N ethyl 2-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-4-ethoxy-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)CC(F)(F)F)C)OCC XGKJBIXDFNAUCV-UHFFFAOYSA-N 0.000 description 2
- SBPMLRXALLHBAG-UHFFFAOYSA-N ethyl 2-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)CC(F)(F)F)C)OC SBPMLRXALLHBAG-UHFFFAOYSA-N 0.000 description 2
- BIFWJUXDPZAHNG-UHFFFAOYSA-N ethyl 2-cyclopropyl-5-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound C(C)OC(=O)C1=C(OC(=C1)C1=CC=2N(C=C1)N=CC2C=2C(=NOC2C)C)C2CC2 BIFWJUXDPZAHNG-UHFFFAOYSA-N 0.000 description 2
- XQLPOZKNLSNUTH-UHFFFAOYSA-N ethyl 4-(2,2,2-trifluoroethoxy)-2-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)C)C)OCC(F)(F)F XQLPOZKNLSNUTH-UHFFFAOYSA-N 0.000 description 2
- HPIFCXDUOSLRQV-UHFFFAOYSA-N ethyl 4-(difluoromethyl)-2-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound FC(C=1N=C(SC=1C(=O)OCC)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C(C)C)C)F HPIFCXDUOSLRQV-UHFFFAOYSA-N 0.000 description 2
- PFGUNENOVGJFHJ-UHFFFAOYSA-N ethyl 4-cyclopropyl-2-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)C)C)C2CC2 PFGUNENOVGJFHJ-UHFFFAOYSA-N 0.000 description 2
- UIPVQBGWEYTZHS-UHFFFAOYSA-N ethyl 4-cyclopropyl-2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2C=2C(=NOC2C)C)C2CC2 UIPVQBGWEYTZHS-UHFFFAOYSA-N 0.000 description 2
- TWRJCZJUAIQBQK-UHFFFAOYSA-N ethyl 4-cyclopropyl-2-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound C1(CC1)C=1N=C(SC=1C(=O)OCC)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)C(C)C)C TWRJCZJUAIQBQK-UHFFFAOYSA-N 0.000 description 2
- CJWMTBMQMQBGLM-UHFFFAOYSA-N ethyl 4-cyclopropyl-2-[3-[3,5-dimethyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound C1(CC1)C=1N=C(SC=1C(=O)OCC)C1=CC=2N(C=C1)N=CC=2C=1C(=NN(C=1C)CC(F)(F)F)C CJWMTBMQMQBGLM-UHFFFAOYSA-N 0.000 description 2
- UKIAKSFCHZSODC-UHFFFAOYSA-N ethyl 5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound C(C)OC(=O)C1=COC(=C1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)C)C UKIAKSFCHZSODC-UHFFFAOYSA-N 0.000 description 2
- YPOOJMLUNWNJTA-UHFFFAOYSA-N ethyl 5-[3-(1,3-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound C(C)OC(=O)C1=COC(=C1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2)C)C YPOOJMLUNWNJTA-UHFFFAOYSA-N 0.000 description 2
- ARUGCYOXSSJEOS-UHFFFAOYSA-N ethyl 5-[3-(1-ethyl-3,5-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound C1=2C=C(C3=CC(C(=O)OCC)=CO3)C=CN1N=CC=2C1=C(C)N(N=C1C)CC ARUGCYOXSSJEOS-UHFFFAOYSA-N 0.000 description 2
- KUUABKDJKQUPQG-UHFFFAOYSA-N ethyl 5-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound C=12N(N=CC=1C1=C(C)ON=C1C)C=CC(=C2)C1=CC(C(=O)OCC)=CO1 KUUABKDJKQUPQG-UHFFFAOYSA-N 0.000 description 2
- YIAGRYZZCKWNJV-UHFFFAOYSA-N ethyl 5-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound C1=C(C=2OC=C(C(=O)OCC)C=2)C=CN2C1=C(C=N2)C1=C(C)N(N=C1C)C(C)C YIAGRYZZCKWNJV-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 102000004311 liver X receptors Human genes 0.000 description 2
- 108090000865 liver X receptors Proteins 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- 229940087646 methanolamine Drugs 0.000 description 2
- WAPKXNWPZJLKLU-UHFFFAOYSA-N methyl 2-(2-methylpropyl)-5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound COC(=O)C1=C(OC(=C1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)C)C)CC(C)C WAPKXNWPZJLKLU-UHFFFAOYSA-N 0.000 description 2
- HJQLWUVKDUVPIS-UHFFFAOYSA-N methyl 2-[3-(1-ethyl-3,5-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound C(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C=1SC(=CN=1)C(=O)OC)C HJQLWUVKDUVPIS-UHFFFAOYSA-N 0.000 description 2
- FXZNCDJMCZLDDA-UHFFFAOYSA-N methyl 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C=1SC(=CN=1)C(=O)OC)C FXZNCDJMCZLDDA-UHFFFAOYSA-N 0.000 description 2
- WUQVLYNRNBFMDI-UHFFFAOYSA-N methyl 2-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound C(C)(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C=1SC(=CN=1)C(=O)OC)C WUQVLYNRNBFMDI-UHFFFAOYSA-N 0.000 description 2
- NFPUXOSLNTXHHK-UHFFFAOYSA-N methyl 2-cyclopropyl-5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound C1=C(C2=CC(C(=O)OC)=C(C3CC3)O2)C=CN2C1=C(C=N2)C1=C(C)N(N=C1C)C NFPUXOSLNTXHHK-UHFFFAOYSA-N 0.000 description 2
- BKWQDCZWRAZEPT-UHFFFAOYSA-N methyl 2-ethyl-5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound COC(=O)C1=C(OC(=C1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)C)C)CC BKWQDCZWRAZEPT-UHFFFAOYSA-N 0.000 description 2
- MNBNWHGJVAYBAS-UHFFFAOYSA-N methyl 2-methyl-5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound COC(=O)C1=C(OC(=C1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)C)C)C MNBNWHGJVAYBAS-UHFFFAOYSA-N 0.000 description 2
- WMRCIGTULBWUHI-UHFFFAOYSA-N methyl 2-methyl-5-pyrazolo[1,5-a]pyridin-5-ylfuran-3-carboxylate Chemical compound CC1=C(C=C(O1)C2=CC3=CC=NN3C=C2)C(=O)OC WMRCIGTULBWUHI-UHFFFAOYSA-N 0.000 description 2
- PCWCIEHUXXJHIK-UHFFFAOYSA-N methyl 5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound COC(=O)C1=COC(=C1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)C)C PCWCIEHUXXJHIK-UHFFFAOYSA-N 0.000 description 2
- HOLWDWATCQAXLM-UHFFFAOYSA-N methyl 5-[3-(1,5-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound COC(=O)C1=COC(=C1)C1=CC=2N(C=C1)N=CC2C=2C=NN(C2C)C HOLWDWATCQAXLM-UHFFFAOYSA-N 0.000 description 2
- PMBBSMNXRXIFIV-UHFFFAOYSA-N methyl 5-[3-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound CN1N=CC(=C1)C=1C=NN2C=1C=C(C=C2)C1=CC(=CO1)C(=O)OC PMBBSMNXRXIFIV-UHFFFAOYSA-N 0.000 description 2
- VDLOVVHGIKTKRU-UHFFFAOYSA-N methyl 5-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-methylfuran-3-carboxylate Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C1=CC(=C(O1)C)C(=O)OC)C VDLOVVHGIKTKRU-UHFFFAOYSA-N 0.000 description 2
- LPLNLIXLBPOPIQ-UHFFFAOYSA-N methyl 5-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-2-carboxylate Chemical compound CC1=NOC(=C1C=1C=NN2C=1C=C(C=C2)C1=CC=C(O1)C(=O)OC)C LPLNLIXLBPOPIQ-UHFFFAOYSA-N 0.000 description 2
- YRHBGWYSUCXKPU-UHFFFAOYSA-N methyl 5-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound COC(=O)C1=COC(=C1)C1=CC=2N(C=C1)N=CC2C=2C(=NOC2C)C YRHBGWYSUCXKPU-UHFFFAOYSA-N 0.000 description 2
- JXPGJIRFDUWYPF-UHFFFAOYSA-N methyl 5-[3-(3,5-dimethyl-1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-2-carboxylate Chemical compound C(C)(C)N1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C1=CC=C(O1)C(=O)OC)C JXPGJIRFDUWYPF-UHFFFAOYSA-N 0.000 description 2
- YHQPWQLHXYTGIX-UHFFFAOYSA-N methyl 5-[3-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound COC(=O)C1=COC(=C1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2)C)C(F)(F)F YHQPWQLHXYTGIX-UHFFFAOYSA-N 0.000 description 2
- HQEFZABRNVWGBR-UHFFFAOYSA-N methyl 5-bromo-2-methylfuran-3-carboxylate Chemical compound COC(=O)C=1C=C(Br)OC=1C HQEFZABRNVWGBR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-NJFSPNSNSA-N ((18)O)water Chemical compound [18OH2] XLYOFNOQVPJJNP-NJFSPNSNSA-N 0.000 description 1
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- KYLUAQBYONVMCP-UHFFFAOYSA-N (2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P KYLUAQBYONVMCP-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000005926 1,2-dimethylbutyloxy group Chemical group 0.000 description 1
- IBXMKLPFLZYRQZ-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 IBXMKLPFLZYRQZ-UHFFFAOYSA-N 0.000 description 1
- WWASSGBZYSHFBP-UHFFFAOYSA-N 1-[3-[1,5-dimethyl-3-(trifluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-3-methoxypyrazole-4-carboxylic acid Chemical compound CN1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)N1N=C(C(=C1)C(=O)O)OC)C(F)(F)F WWASSGBZYSHFBP-UHFFFAOYSA-N 0.000 description 1
- GDBMFUCGXBMPKS-UHFFFAOYSA-N 1-[3-[1,5-dimethyl-3-(trifluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylic acid Chemical compound CN1N=C(C(=C1C)C=1C=NN2C1C=C(C=C2)N2N=CC(=C2)C(=O)O)C(F)(F)F GDBMFUCGXBMPKS-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- HKCFTGZESMCKJA-UHFFFAOYSA-N 1-pyridin-4-ylimidazolidin-2-one Chemical compound O=C1NCCN1C1=CC=NC=C1 HKCFTGZESMCKJA-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- ZYDUNXCLPOKBNQ-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1,3-dihydropyridine Chemical compound CC1(C)CC=CC(C)(C)N1 ZYDUNXCLPOKBNQ-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- XMQODGUTLZXUGZ-RPBOFIJWSA-N 2-[(3s)-3-[[1-[(2r)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic acid Chemical compound C([C@@H](C(=O)OCC)CC1(CCCC1)C(=O)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XMQODGUTLZXUGZ-RPBOFIJWSA-N 0.000 description 1
- YGZATXCHGKHQEU-UHFFFAOYSA-N 2-[3-[1,5-dimethyl-3-(trifluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylic acid Chemical compound CN1N=C(C(=C1C)C=1C=NN2C=1C=C(C=C2)C=1SC(=C(N=1)OC)C(=O)O)C(F)(F)F YGZATXCHGKHQEU-UHFFFAOYSA-N 0.000 description 1
- ODUOJXZPIYUATO-UHFFFAOYSA-N 2-[[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]amino]acetic acid (phenylmethyl) ester Chemical compound C=1C=CC=CC=1COC(=O)CNC(=O)C(CSC(=O)C)CC1=CC=CC=C1 ODUOJXZPIYUATO-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- VSTDRKAQOCCOLF-UHFFFAOYSA-N 2-chloro-1H-benzo[g]indole Chemical compound ClC=1NC2=C3C(=CC=C2C=1)C=CC=C3 VSTDRKAQOCCOLF-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- YLBSPLBMVIVTPQ-UHFFFAOYSA-N 2-pyrazolo[1,5-a]pyridin-5-yl-4-(trifluoromethyl)-1,3-oxazole-5-carboxylic acid Chemical compound C1=2C=C(C=3OC(=C(N=3)C(F)(F)F)C(=O)O)C=CN1N=CC=2 YLBSPLBMVIVTPQ-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- DUSPIKCOOSCITF-UHFFFAOYSA-N 3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile Chemical compound C1=CC(=CC=2N1N=CC=2C1=C(C)ON=C1C)C#N DUSPIKCOOSCITF-UHFFFAOYSA-N 0.000 description 1
- CFMYAPXBZNPJKI-UHFFFAOYSA-N 3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridine-5-carbothioamide Chemical compound C1=C(C(=S)N)C=CN2C1=C(C=N2)C1=C(C)ON=C1C CFMYAPXBZNPJKI-UHFFFAOYSA-N 0.000 description 1
- OJDZHBWEGLIKRW-UHFFFAOYSA-N 3-[(4-hydroxyphenyl)methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(CC=2C=CC(O)=CC=2)=C1 OJDZHBWEGLIKRW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BJTPLMFKKAIAAI-UHFFFAOYSA-N 3-methoxycarbonyl-5-pyrazolo[1,5-a]pyridin-5-ylfuran-2-carboxylic acid Chemical compound N12C=CC(=CC1=CC=N2)C1=CC(C(=O)OC)=C(C(=O)O)O1 BJTPLMFKKAIAAI-UHFFFAOYSA-N 0.000 description 1
- FCOVWHUANKYKPT-UHFFFAOYSA-N 3-methyl-1-propan-2-yl-5-(trifluoromethyl)pyrazole Chemical compound CC(C)N1N=C(C)C=C1C(F)(F)F FCOVWHUANKYKPT-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 description 1
- GNXWITGSOFQXDG-UHFFFAOYSA-N 4-bromo-3,5-dimethyl-1-phenylpyrazole Chemical compound CC1=C(Br)C(C)=NN1C1=CC=CC=C1 GNXWITGSOFQXDG-UHFFFAOYSA-N 0.000 description 1
- ATQQXTKWOFDKJP-UHFFFAOYSA-N 4-bromo-5-methyl-1-propan-2-yl-3-(trifluoromethyl)pyrazole Chemical compound CC(C)N1N=C(C(F)(F)F)C(Br)=C1C ATQQXTKWOFDKJP-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- ABXBHZQYWYEFHC-UHFFFAOYSA-N 5,5,5-trifluoro-4-hydroxy-4-(2,2,6,6-tetramethylpiperidin-1-yl)pentan-2-one Chemical compound C1CCC(C)(C)N(C1(C)C)C(C(F)(F)F)(CC(=O)C)O ABXBHZQYWYEFHC-UHFFFAOYSA-N 0.000 description 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
- REBSMYOUWCHBEY-UHFFFAOYSA-N 5-methyl-1-propan-2-yl-3-(trifluoromethyl)pyrazole Chemical compound CC(C)N1N=C(C(F)(F)F)C=C1C REBSMYOUWCHBEY-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- DVWPYSZEIPNYFJ-UHFFFAOYSA-N 5-pyrazolo[1,5-a]pyridin-5-ylfuran-3-carboxylic acid Chemical compound C1=C(C2=CC(C(=O)O)=CO2)C=CN2C1=CC=N2 DVWPYSZEIPNYFJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000020576 Adrenal disease Diseases 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 101100096578 Arabidopsis thaliana SQD2 gene Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- HFVCQSSEDXQLSG-UHFFFAOYSA-N ClC(C(=O)O)C(=O)C1CC1 Chemical compound ClC(C(=O)O)C(=O)C1CC1 HFVCQSSEDXQLSG-UHFFFAOYSA-N 0.000 description 1
- HKUQCNWMEZLHHC-UHFFFAOYSA-N ClC=1C(OC=CC1)C(=N)N Chemical compound ClC=1C(OC=CC1)C(=N)N HKUQCNWMEZLHHC-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000030202 Dietary Animal Proteins Human genes 0.000 description 1
- 108091004234 Dietary Animal Proteins Proteins 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- NHXSTXWKZVAVOQ-UHFFFAOYSA-N Ethyl furoate Chemical compound CCOC(=O)C1=CC=CO1 NHXSTXWKZVAVOQ-UHFFFAOYSA-N 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 229910017333 Mo(CO)6 Inorganic materials 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-BJUDXGSMSA-N Nitrogen-13 Chemical compound [13N] QJGQUHMNIGDVPM-BJUDXGSMSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102100040902 PAS domain-containing serine/threonine-protein kinase Human genes 0.000 description 1
- 101710158749 PAS domain-containing serine/threonine-protein kinase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 1
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 description 1
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 102000018692 Sulfonylurea Receptors Human genes 0.000 description 1
- 108010091821 Sulfonylurea Receptors Proteins 0.000 description 1
- NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- QOJROSVHDGVEAI-UHFFFAOYSA-N [3,5-dimethyl-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrazol-4-yl]boronic acid Chemical compound CC1=NN(C(=O)OC(C)(C)C)C(C)=C1B(O)O QOJROSVHDGVEAI-UHFFFAOYSA-N 0.000 description 1
- LKCKJNCNCZVQRZ-UHFFFAOYSA-M [Br-].C(C1=CC=CC=C1)C[N+]1=CSC=C1 Chemical compound [Br-].C(C1=CC=CC=C1)C[N+]1=CSC=C1 LKCKJNCNCZVQRZ-UHFFFAOYSA-M 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- MKOMESMZHZNBIZ-UHFFFAOYSA-M alagebrium Chemical compound [Cl-].CC1=C(C)SC=[N+]1CC(=O)C1=CC=CC=C1 MKOMESMZHZNBIZ-UHFFFAOYSA-M 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 description 1
- 229960003550 alosetron Drugs 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- WRPCDQFKIDRUIU-UHFFFAOYSA-N aniline furan Chemical compound C=1C=COC=1.NC1=CC=CC=C1 WRPCDQFKIDRUIU-UHFFFAOYSA-N 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- AAMATCKFMHVIDO-UHFFFAOYSA-N azane;1h-pyrrole Chemical compound N.C=1C=CNC=1 AAMATCKFMHVIDO-UHFFFAOYSA-N 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 229960002837 benzphetamine Drugs 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- VEXZGXHMUGYJMC-OUBTZVSYSA-N chlorane Chemical compound [36ClH] VEXZGXHMUGYJMC-OUBTZVSYSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical group [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- NCNFDKWULDWJDS-OAHLLOKOSA-N cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 description 1
- 229960002099 cilansetron Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000012696 congenital leptin deficiency Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- KRMORCCAHXFIHF-UHFFFAOYSA-N ethyl 1,3-oxazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=CO1 KRMORCCAHXFIHF-UHFFFAOYSA-N 0.000 description 1
- ZGZVRDOOYSXWAO-UHFFFAOYSA-N ethyl 1-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylate Chemical compound C(C)OC(=O)C=1C=NN(C1)C1=CC=2N(C=C1)N=CC2C=2C(=NOC2C)C ZGZVRDOOYSXWAO-UHFFFAOYSA-N 0.000 description 1
- MJQXRYZZLRAGDF-UHFFFAOYSA-N ethyl 1-[3-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylate Chemical compound C(C)OC(=O)C=1C=NN(C1)C1=CC=2N(C=C1)N=CC2C=2C(=NNC2C)C MJQXRYZZLRAGDF-UHFFFAOYSA-N 0.000 description 1
- XYJBJWAYLDXAOY-GZTJUZNOSA-N ethyl 1-[3-[(Z)-2-hydroxy-4-oxopent-2-en-3-yl]pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylate Chemical compound C(C)OC(=O)C=1C=NN(C1)C1=CC=2N(C=C1)N=CC2/C(=C(\C)/O)/C(C)=O XYJBJWAYLDXAOY-GZTJUZNOSA-N 0.000 description 1
- JWFVLIXJGBAQJT-UHFFFAOYSA-N ethyl 1-[3-[5-methyl-1-propan-2-yl-3-(trifluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]pyrazole-4-carboxylate Chemical compound C(C)OC(=O)C=1C=NN(C1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)C(C)C)C(F)(F)F JWFVLIXJGBAQJT-UHFFFAOYSA-N 0.000 description 1
- MRFHFJUDFVXCDV-UHFFFAOYSA-N ethyl 1-pyrazolo[1,5-a]pyridin-5-yl-3-(trifluoromethyl)pyrazole-4-carboxylate Chemical compound C(C)OC(=O)C=1C(=NN(C1)C1=CC=2N(C=C1)N=CC2)C(F)(F)F MRFHFJUDFVXCDV-UHFFFAOYSA-N 0.000 description 1
- LJNFEUFHOQBQCK-UHFFFAOYSA-N ethyl 1-pyrazolo[1,5-a]pyridin-5-ylpyrazole-4-carboxylate Chemical compound C(C)OC(=O)C=1C=NN(C1)C1=CC=2N(C=C1)N=CC2 LJNFEUFHOQBQCK-UHFFFAOYSA-N 0.000 description 1
- FNYHOYCLAYTSAG-UHFFFAOYSA-N ethyl 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-4-hydroxy-1,3-thiazole-5-carboxylate Chemical compound C1=C(C=2SC(C(=O)OCC)=C(N=2)O)C=CN2C1=C(C=N2)C1=C(C)ON=C1C FNYHOYCLAYTSAG-UHFFFAOYSA-N 0.000 description 1
- JNKQFYYNYNARIQ-UHFFFAOYSA-N ethyl 2-[3-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-oxazole-5-carboxylate Chemical compound C(C)OC(=O)C1=CN=C(O1)C1=CC=2N(C=C1)N=CC2C=2C(=NNC2C)C JNKQFYYNYNARIQ-UHFFFAOYSA-N 0.000 description 1
- ZMSLMHRCXMTXEX-XNTDXEJSSA-N ethyl 2-[3-[(Z)-2-hydroxy-4-oxopent-2-en-3-yl]pyrazolo[1,5-a]pyridin-5-yl]-4-methoxy-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2/C(=C(\C)/O)/C(C)=O)OC ZMSLMHRCXMTXEX-XNTDXEJSSA-N 0.000 description 1
- WVDBGSRBDGFXJU-UHFFFAOYSA-N ethyl 2-[3-[1-(difluoromethyl)-3,5-dimethylpyrazol-4-yl]pyrazolo[1,5-a]pyridin-5-yl]-4-ethoxy-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2C=2C(=NN(C2C)C(F)F)C)OCC WVDBGSRBDGFXJU-UHFFFAOYSA-N 0.000 description 1
- ULEPUYBUMTXCHV-UHFFFAOYSA-N ethyl 2-bromo-5-[3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound C1=C(C2=CC(C(=O)OCC)=C(Br)O2)C=CN2C1=C(C=N2)C1=C(C)ON=C1C ULEPUYBUMTXCHV-UHFFFAOYSA-N 0.000 description 1
- RGTIQKPWQJFGFH-UHFFFAOYSA-N ethyl 2-chloro-4,4-difluoro-3-oxobutanoate Chemical compound CCOC(=O)C(Cl)C(=O)C(F)F RGTIQKPWQJFGFH-UHFFFAOYSA-N 0.000 description 1
- OARMSGSFZBIXSF-UHFFFAOYSA-N ethyl 2-pyrazolo[1,5-a]pyridin-5-yl-1,3-oxazole-4-carboxylate Chemical compound C1=C(C2=NC(=CO2)C(=O)OCC)C=CN2C1=CC=N2 OARMSGSFZBIXSF-UHFFFAOYSA-N 0.000 description 1
- USJYIGKIVPJWIC-UHFFFAOYSA-N ethyl 2-pyrazolo[1,5-a]pyridin-5-yl-1,3-oxazole-5-carboxylate Chemical compound C(C)OC(=O)C1=CN=C(O1)C1=CC=2N(C=C1)N=CC2 USJYIGKIVPJWIC-UHFFFAOYSA-N 0.000 description 1
- PFZXNJOTDYTTPR-UHFFFAOYSA-N ethyl 2-pyrazolo[1,5-a]pyridin-5-yl-4-(2,2,2-trifluoroethoxy)-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2)OCC(F)(F)F PFZXNJOTDYTTPR-UHFFFAOYSA-N 0.000 description 1
- HAMILRWAORFOOP-UHFFFAOYSA-N ethyl 3-methoxy-1-pyrazolo[1,5-a]pyridin-5-ylpyrazole-4-carboxylate Chemical compound C1=C(N2C=C(C(=O)OCC)C(OC)=N2)C=CN2C1=CC=N2 HAMILRWAORFOOP-UHFFFAOYSA-N 0.000 description 1
- BPACQTLDGZUEBB-UHFFFAOYSA-N ethyl 4-(difluoromethyl)-2-pyrazolo[1,5-a]pyridin-5-yl-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2)C(F)F BPACQTLDGZUEBB-UHFFFAOYSA-N 0.000 description 1
- LCFHIAZOPJEWJV-GZTJUZNOSA-N ethyl 4-cyclopropyl-2-[3-[(Z)-2-hydroxy-4-oxopent-2-en-3-yl]pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2/C(=C(\C)/O)/C(C)=O)C2CC2 LCFHIAZOPJEWJV-GZTJUZNOSA-N 0.000 description 1
- AXAVWQCAVXZFRM-UHFFFAOYSA-N ethyl 4-cyclopropyl-2-pyrazolo[1,5-a]pyridin-5-yl-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2)C2CC2 AXAVWQCAVXZFRM-UHFFFAOYSA-N 0.000 description 1
- MUGRJUQIZUHFJX-LFIBNONCSA-N ethyl 4-ethoxy-2-[3-[(Z)-2-hydroxy-4-oxopent-2-en-3-yl]pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2/C(=C(\C)/O)/C(C)=O)OCC MUGRJUQIZUHFJX-LFIBNONCSA-N 0.000 description 1
- HMHIYXRVIRWCLW-UHFFFAOYSA-N ethyl 4-ethoxy-2-pyrazolo[1,5-a]pyridin-5-yl-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2)OCC HMHIYXRVIRWCLW-UHFFFAOYSA-N 0.000 description 1
- HQWRLESDTMZYCE-UHFFFAOYSA-N ethyl 4-hydroxy-2-pyrazolo[1,5-a]pyridin-5-yl-1,3-thiazole-5-carboxylate Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=CC=2N(C=C1)N=CC2)O HQWRLESDTMZYCE-UHFFFAOYSA-N 0.000 description 1
- VYXIHSAEOXPAEY-UHFFFAOYSA-N ethyl 5-(trifluoromethyl)-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1C(F)(F)F VYXIHSAEOXPAEY-UHFFFAOYSA-N 0.000 description 1
- LVNOVYQAYQDEOE-UHFFFAOYSA-N ethyl 5-[3-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound C1=2C=C(C3=CC(C(=O)OCC)=CO3)C=CN1N=CC=2C1=C(C)NN=C1C LVNOVYQAYQDEOE-UHFFFAOYSA-N 0.000 description 1
- POWYWWSYLJIKLT-WOJGMQOQSA-N ethyl 5-[3-[(Z)-2-hydroxy-4-oxopent-2-en-3-yl]pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound C1=C(C2=CC(C(=O)OCC)=CO2)C=CN2C1=C(C=N2)/C(=C(\C)/O)/C(=O)C POWYWWSYLJIKLT-WOJGMQOQSA-N 0.000 description 1
- VOWGWQQKEIBDSQ-UHFFFAOYSA-N ethyl 5-methyl-2-pyrazolo[1,5-a]pyridin-5-yl-1,3-oxazole-4-carboxylate Chemical compound C(C)OC(=O)C=1N=C(OC1C)C1=CC=2N(C=C1)N=CC2 VOWGWQQKEIBDSQ-UHFFFAOYSA-N 0.000 description 1
- HXNCBPFNFHRRFJ-UHFFFAOYSA-N ethyl 5-pyrazolo[1,5-a]pyridin-5-ylfuran-3-carboxylate Chemical compound C(C)OC(=O)C1=COC(=C1)C1=CC=2N(C=C1)N=CC2 HXNCBPFNFHRRFJ-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 238000007037 hydroformylation reaction Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Substances [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 description 1
- 229960002137 melagatran Drugs 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- JGJDORZNOSWWDS-UHFFFAOYSA-N methyl 1,3-oxazole-5-carboxylate Chemical compound COC(=O)C1=CN=CO1 JGJDORZNOSWWDS-UHFFFAOYSA-N 0.000 description 1
- XPQIUPLRTZOMSX-UHFFFAOYSA-N methyl 2-[3-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound COC(=O)C1=CN=C(S1)C1=CC=2N(C=C1)N=CC2C=2C(=NNC2C)C XPQIUPLRTZOMSX-UHFFFAOYSA-N 0.000 description 1
- KTSMVYYIQJMECC-OQLLNIDSSA-N methyl 2-[3-[(Z)-2-hydroxy-4-oxopent-2-en-3-yl]pyrazolo[1,5-a]pyridin-5-yl]-1,3-thiazole-5-carboxylate Chemical compound C=12N(N=CC=1/C(=C(\C)/O)/C(=O)C)C=CC(=C2)C=1SC(=CN=1)C(=O)OC KTSMVYYIQJMECC-OQLLNIDSSA-N 0.000 description 1
- HNLVIKMXFBRZDF-UHFFFAOYSA-N methyl 2-bromo-1,3-thiazole-5-carboxylate Chemical compound COC(=O)C1=CN=C(Br)S1 HNLVIKMXFBRZDF-UHFFFAOYSA-N 0.000 description 1
- IIMYBIPYAKIOKY-UHFFFAOYSA-N methyl 2-bromo-5-[3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-3-carboxylate Chemical compound C1=2C=C(C3=CC(C(=O)OC)=C(Br)O3)C=CN1N=CC=2C1=C(C)N(N=C1C)C IIMYBIPYAKIOKY-UHFFFAOYSA-N 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- JDTJMSRDMQFEOQ-UHFFFAOYSA-N methyl 2-pyrazolo[1,5-a]pyridin-5-yl-1,3-thiazole-5-carboxylate Chemical compound COC(=O)C1=CN=C(S1)C1=CC=2N(C=C1)N=CC2 JDTJMSRDMQFEOQ-UHFFFAOYSA-N 0.000 description 1
- QTZYIFQWCINOTH-UHFFFAOYSA-N methyl 2-pyrazolo[1,5-a]pyridin-5-yl-4-(trifluoromethyl)-1,3-oxazole-5-carboxylate Chemical compound COC(=O)C1=C(N=C(O1)C1=CC=2N(C=C1)N=CC2)C(F)(F)F QTZYIFQWCINOTH-UHFFFAOYSA-N 0.000 description 1
- JSWFVHORYISEGL-UHFFFAOYSA-N methyl 5-[3-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-5-yl]furan-2-carboxylate Chemical compound C=12N(N=CC=1C1=C(C)NN=C1C)C=CC(=C2)C=1OC(=CC=1)C(=O)OC JSWFVHORYISEGL-UHFFFAOYSA-N 0.000 description 1
- IGPMLXJPEHHPGR-LICLKQGHSA-N methyl 5-[3-[(Z)-2-hydroxy-4-oxopent-2-en-3-yl]pyrazolo[1,5-a]pyridin-5-yl]furan-2-carboxylate Chemical compound COC(=O)C=1OC(=CC1)C1=CC=2N(C=C1)N=CC2/C(=C(\C)/O)/C(C)=O IGPMLXJPEHHPGR-LICLKQGHSA-N 0.000 description 1
- QEJBKKLWFBFKLK-UHFFFAOYSA-N methyl 5-pyrazolo[1,5-a]pyridin-5-ylfuran-2-carboxylate Chemical compound COC(=O)C=1OC(=CC1)C1=CC=2N(C=C1)N=CC2 QEJBKKLWFBFKLK-UHFFFAOYSA-N 0.000 description 1
- ZKHQSQYLKSSYIP-UHFFFAOYSA-N methyl furan-3-carboxylate Chemical compound COC(=O)C=1C=COC=1 ZKHQSQYLKSSYIP-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- BZIVQLROJQFXCQ-UHFFFAOYSA-N n'-methylsulfonyl-1-(2-oxo-2-thiophen-2-ylethyl)pyridin-1-ium-3-carbohydrazide;bromide Chemical compound [Br-].CS(=O)(=O)NNC(=O)C1=CC=C[N+](CC(=O)C=2SC=CC=2)=C1 BZIVQLROJQFXCQ-UHFFFAOYSA-N 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- VLZLOWPYUQHHCG-UHFFFAOYSA-N nitromethylbenzene Chemical compound [O-][N+](=O)CC1=CC=CC=C1 VLZLOWPYUQHHCG-UHFFFAOYSA-N 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 atom Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229960002131 palonosetron Drugs 0.000 description 1
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940097886 phosphorus 32 Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- NPUSXSOBPNHOPH-UHFFFAOYSA-N propan-2-yl 4-(2-chlorophenyl)-1-ethyl-2-methyl-5-oxo-4,7-dihydrofuro[3,4-b]pyridine-3-carboxylate Chemical compound CC(C)OC(=O)C1=C(C)N(CC)C(COC2=O)=C2C1C1=CC=CC=C1Cl NPUSXSOBPNHOPH-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- FZZIMJSZKISMSE-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine Chemical compound C1=C[CH]N2N=C=CC2=C1 FZZIMJSZKISMSE-UHFFFAOYSA-N 0.000 description 1
- PRDWHYXLYTVDBZ-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine-5-carbothioamide Chemical compound N1=CC=C2N1C=CC(=C2)C(N)=S PRDWHYXLYTVDBZ-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004590 pyridopyridyl group Chemical group N1=C(C=CC2=C1C=CC=N2)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960002281 racecadotril Drugs 0.000 description 1
- 108700040249 racecadotril Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229950003039 renzapride Drugs 0.000 description 1
- GZSKEXSLDPEFPT-IINYFYTJSA-N renzapride Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@H]1[C@H](C2)CCC[N@]2CC1 GZSKEXSLDPEFPT-IINYFYTJSA-N 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- IMNTVVOUWFPRSB-JWQCQUIFSA-N sch-48461 Chemical compound C1=CC(OC)=CC=C1[C@H]1N(C=2C=CC(OC)=CC=2)C(=O)[C@@H]1CCCC1=CC=CC=C1 IMNTVVOUWFPRSB-JWQCQUIFSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000849 selective androgen receptor modulator Substances 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- PUZPDOWCWNUUKD-ULWFUOSBSA-M sodium;fluorine-18(1-) Chemical compound [18F-].[Na+] PUZPDOWCWNUUKD-ULWFUOSBSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 239000008117 stearic acid Chemical group 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229960002876 tegaserod Drugs 0.000 description 1
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940083085 thiazide derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LZGVDNRJCGPNDS-UHFFFAOYSA-N trinitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)[N+]([O-])=O LZGVDNRJCGPNDS-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-OUBTZVSYSA-N water-17o Chemical compound [17OH2] XLYOFNOQVPJJNP-OUBTZVSYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229950004681 zacopride Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1902490.0 | 2019-02-25 | ||
| GBGB1902490.0A GB201902490D0 (en) | 2019-02-25 | 2019-02-25 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202045505A true TW202045505A (zh) | 2020-12-16 |
Family
ID=65998935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109105861A TW202045505A (zh) | 2019-02-25 | 2020-02-24 | 用於疾病之治療之新穎化合物及其醫藥組合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220144823A1 (https=) |
| EP (1) | EP3931191B1 (https=) |
| JP (1) | JP2022525121A (https=) |
| KR (1) | KR20210134001A (https=) |
| CN (1) | CN113474344A (https=) |
| AR (1) | AR124749A1 (https=) |
| AU (1) | AU2020229041A1 (https=) |
| BR (1) | BR112021016642A2 (https=) |
| CA (1) | CA3130154A1 (https=) |
| CO (1) | CO2021010485A2 (https=) |
| ES (1) | ES2963409T3 (https=) |
| GB (1) | GB201902490D0 (https=) |
| IL (1) | IL285751A (https=) |
| MA (1) | MA55074A (https=) |
| MX (1) | MX2021010093A (https=) |
| PH (1) | PH12021552032A1 (https=) |
| SG (1) | SG11202109157TA (https=) |
| TW (1) | TW202045505A (https=) |
| WO (1) | WO2020173739A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022070288A1 (ja) * | 2020-09-30 | 2022-04-07 | 旭化成ファーマ株式会社 | 含窒素二環化合物 |
| WO2025143152A1 (ja) * | 2023-12-27 | 2025-07-03 | 全薬工業株式会社 | チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7074801B1 (en) * | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| JP2011530511A (ja) * | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| WO2010090716A1 (en) * | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| US10392389B2 (en) * | 2012-10-25 | 2019-08-27 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of PASK |
| CA2969265A1 (en) * | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use |
| EP3615538B1 (en) * | 2017-04-27 | 2024-02-07 | The Brigham and Women's Hospital, Inc. | Novel alk2 inhibitors and methods for inhibiting bmp signaling |
-
2019
- 2019-02-25 GB GBGB1902490.0A patent/GB201902490D0/en not_active Ceased
-
2020
- 2020-02-17 AU AU2020229041A patent/AU2020229041A1/en not_active Abandoned
- 2020-02-17 SG SG11202109157TA patent/SG11202109157TA/en unknown
- 2020-02-17 ES ES20706194T patent/ES2963409T3/es active Active
- 2020-02-17 WO PCT/EP2020/054122 patent/WO2020173739A1/en not_active Ceased
- 2020-02-17 EP EP20706194.6A patent/EP3931191B1/en active Active
- 2020-02-17 CA CA3130154A patent/CA3130154A1/en active Pending
- 2020-02-17 US US17/433,503 patent/US20220144823A1/en not_active Abandoned
- 2020-02-17 BR BR112021016642A patent/BR112021016642A2/pt not_active IP Right Cessation
- 2020-02-17 MX MX2021010093A patent/MX2021010093A/es unknown
- 2020-02-17 PH PH1/2021/552032A patent/PH12021552032A1/en unknown
- 2020-02-17 CN CN202080016700.3A patent/CN113474344A/zh active Pending
- 2020-02-17 MA MA055074A patent/MA55074A/fr unknown
- 2020-02-17 JP JP2021555034A patent/JP2022525121A/ja active Pending
- 2020-02-17 KR KR1020217030814A patent/KR20210134001A/ko not_active Ceased
- 2020-02-21 AR ARP200100485A patent/AR124749A1/es not_active Application Discontinuation
- 2020-02-24 TW TW109105861A patent/TW202045505A/zh unknown
-
2021
- 2021-08-10 CO CONC2021/0010485A patent/CO2021010485A2/es unknown
- 2021-08-22 IL IL285751A patent/IL285751A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3130154A1 (en) | 2020-09-03 |
| SG11202109157TA (en) | 2021-09-29 |
| MA55074A (fr) | 2022-01-05 |
| ES2963409T3 (es) | 2024-03-27 |
| MX2021010093A (es) | 2021-09-21 |
| BR112021016642A2 (pt) | 2021-11-03 |
| KR20210134001A (ko) | 2021-11-08 |
| IL285751A (en) | 2021-10-31 |
| US20220144823A1 (en) | 2022-05-12 |
| PH12021552032A1 (en) | 2022-11-14 |
| AU2020229041A1 (en) | 2021-10-21 |
| WO2020173739A1 (en) | 2020-09-03 |
| EP3931191A1 (en) | 2022-01-05 |
| GB201902490D0 (en) | 2019-04-10 |
| CN113474344A (zh) | 2021-10-01 |
| JP2022525121A (ja) | 2022-05-11 |
| EP3931191B1 (en) | 2023-10-04 |
| CO2021010485A2 (es) | 2021-08-19 |
| AR124749A1 (es) | 2023-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3043457T3 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| KR102824962B1 (ko) | 헤테로시클릭 rip1 억제 화합물 | |
| RU2684641C1 (ru) | Производные пиразолопиридина в качестве модуляторов активности tnf | |
| JP6001048B2 (ja) | チアゾロピリミジン化合物 | |
| CN117355532A (zh) | 三并环类usp1抑制剂及其用途 | |
| KR20250172881A (ko) | 글루코스-의존성 인슐린 분비 촉진 폴리펩티드 수용체 길항제 및 이의 용도 | |
| US20240246932A1 (en) | Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| JP2021526123A (ja) | オートタキシン阻害剤とその使用 | |
| KR20140117427A (ko) | 염증성 질환의 치료를 위한 신규의 다이하이드로피리미디노아이소퀴놀리논 및 그의 약학 조성물 | |
| WO2007037534A1 (ja) | ２－へテロアリール置換インドール誘導体 | |
| CN109890827A (zh) | 螺环化合物 | |
| PH12015502055B1 (en) | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| JP2021535164A (ja) | 心筋サルコメア阻害剤 | |
| JP2018138609A (ja) | ナフチリジンジオン誘導体 | |
| KR20220002903A (ko) | 과혈당증의 치료에 유용한 헤테로아릴(헤테로시클릴)메탄올 화합물 | |
| EP3250561A1 (en) | Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof | |
| TW202045505A (zh) | 用於疾病之治療之新穎化合物及其醫藥組合物 | |
| EP1683798B1 (en) | Fused polycyclic compounds having heterocycle and medicinal use thereof | |
| ES2641469T3 (es) | Compuesto de 2-piridona | |
| CN120535527A (zh) | 一类含氮稠环类化合物、制备方法和用途 | |
| KR101858881B1 (ko) | 4-｛4-[(1e)-4-(2,9-디아자스피로[5.5]운데스-2-일)부트-1-엔-1-일]-2-메틸벤질｝-5-(프로판-2-일)-1h-피라졸-3-일 베타-d-글루코피라노시드 아세테이트 | |
| US20250235510A1 (en) | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist peptides | |
| EP4522604A1 (en) | Inhibitors of human respiratory syncytial virus and metapneumovirus | |
| WO2025172535A1 (en) | Indole and benzimidazole compounds as factor b inhibitors | |
| KR20230154382A (ko) | 신규한 pim 키나아제 억제 화합물 및 이의 용도 |